Head-to-head · WeighScore
CoreAge Rx vs Harper Meds
The verdict
CoreAge Rx takes it — 91.8/100 to 68.4/100.
CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
CoreAge Rx is also our overall #1 pick — it tops the full scorecard at 91.8/100 (A−).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | CoreAge Rx | Harper Meds |
|---|---|---|
| WeighScore | 91.8/100 | 68.4/100 |
| Grade | A− | C |
| Scorecard rank | #1 | #164 |
| Semaglutide | $99/mo | $149/mo |
| Tirzepatide | $149/mo | $196/mo |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #1 · A−
Strengths
- Flat all-in price with no month-two step-up
- Semaglutide and tirzepatide on one account
- All 50 states, LegitScript-verified
Where it loses points
- Not the cheapest sticker price
- Compounded only
- Pharmacy partner not yet publicly named
Graded #164 · C
FDAWarning letter issued to Nexus Health Solutions LLC dba Harper Meds in June 2026. See the FDA warning-letter database.
Strengths
- Flat pricing — same cost at every dose, no escalation as you titrate up
- All-inclusive: doctor consultation, prescription, medication, and free shipping in one price
- LegitScript-certified; prescriptions reviewed by US-licensed M.D.s
- Offers both compounded semaglutide ($149/mo) and tirzepatide ($196/mo)
Where it loses points
- Membership fee is non-refundable once paid
- Partner pharmacy is not publicly named
- State availability not published (limited to 'certain states')
- FDA issued Nexus Health Solutions LLC dba Harper Meds a warning letter in June 2026; the letter is public in FDA's warning-letter database
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.